Pyrrolo[2,3-D]imidazoles for the treatment of hyperproliferative disorders

A compound represented by Formula (I)

• or a pharmaceutically acceptable salt or N-oxide thereof, wherein
• A is C0-6alkyl or —NR1R11;
• E is —CO2R2, —CONR12R21, —C(RaRb)OR212, or —C(RaRb)NR12R2;
• D is aryl or hetaryl;
• G is C0-6alkyl, halogen, optionally substituted cyclyl, optionally substituted heterocyclyl, —OR22, —NR13R22, —CN or —CF3;
• R1, R11, R12, R212, and R13 each independently is C0-6alkyl, —COR14, —CONR14R15, or —S(O)nNR14R15;
• R14 and R15 each independently is C0-6alkyl, —CO(C0-6alkyl), —CON(C0-6alkyl)(C0-6alkyl), or —S(O)mN(C0-6alkyl)(C0-6alkyl);
• R2 and R22 each independently is C1-8alkyl optionally substituted with a heterocyclyl;
• —C0-8alkyl-C3-8cycloalkyl, —C2-8alkyl-O—C0-8alkyl, —C2-8alkyl-N(C0-8alkyl)(C0-8alkyl), —C2-8alkyl-S(O)0-2—C0-8alkyl;
• or heterocyclyl optionally substituted with C0-8alkyl, cyclyl or substituted cyclyl substituent;
• R21 is C0-8alkyl optionally substituted with a heterocyclyl;
• R21 is —C0-8alkyl-C3-8cycloalkyl, —C2-8alkyl-O—C0-8alkyl, —C2-8alkyl-N(C0-8alkyl)(C0-8alkyl), or —C2-8alkyl-S(O)0-2—C0-8alkyl;
• or R21 is heterocyclyl optionally substituted with C0-8alkyl, cyclyl or substituted cyclyl substituent;
• Ra and Rb are each independently C0-8alkyl or C3-8cycloalkyl;
• or Ra and Rb taken together with the C to which they are attached form a saturated or partially unsaturated 3-10 membered ring optionally containing 0-4 N, O, S, SO, or SO2 at the ring nodes, provided that no N, O or S atoms are placed adjacent to each other at ring nodes;
• and
• n and m each independently is 0, 1, or 2.